Details of the Drug Combination

General Information of Drug Combination (ID: DCPPAQK)

Drug Combination Name
JQ1 Nintedanib
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs JQ1   DM3XQDH Nintedanib   DMMQ2OW
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 0.456
Bliss Independence Score: 3.398
Loewe Additivity Score: 4.094
LHighest Single Agent (HSA) Score: 5.578

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JQ1
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [2]
JQ1 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN bromodomain-containing protein 2 (BRD2) TTNISW6 BRD2_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Nintedanib
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Approved [3]
Non-small-cell lung cancer 2C25.Y Approved [4]
Ovarian neoplasm N.A. Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Uncovering the Role of BRD2 in COVID-19. 2020-03-19
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 205832
4 Nintedanib FDA Label
5 ClinicalTrials.gov (NCT04338802) Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19. U.S. National Institutes of Health.